LEADER 01787nam 2200361 450 001 9910765774603321 005 20230324064037.0 010 $a3-03842-948-1 035 $a(CKB)5400000000000479 035 $a(NjHacI)995400000000000479 035 $a(EXLCZ)995400000000000479 100 $a20230324d2018 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAntiphospholipid Antibodies and Syndrome /$fedited by Ricard Cervera 210 1$aBasel :$cMDPI,$d2018. 210 4$dİ2018 215 $a1 online resource (vii, 125 pages) $cillustrations 320 $aIncludes bibliographical references. 330 $aAntiphospholipid syndrome (APS) is an autoimmune disorder caused by antiphospholipid antibodies. It was characterized by excessive clotting of blood and/or certain complications of pregnancy (premature miscarriages, unexplained fetal death, or premature birth) and the presence of antiphospholipid antibodies (such as anti-cardiolipin antibodies or lupus anticoagulant) in the blood. Fifty percent of people with lupus have APS. The exact pathogenesis of APS is inadequately understood, so no specific treatment is available. This Special Issue of Antibodies focuses on the symptoms, pathogenesis, diagnosis, clinical manifestation, therapy of APS, the new research development of antiphospholipid antibodies, and all the other aspects of APS. 606 $aAntiphospholipid syndrome 615 0$aAntiphospholipid syndrome. 676 $a616.978 702 $aCervera$b Ricard 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910765774603321 996 $aAntiphospholipid Antibodies and Syndrome$92937410 997 $aUNINA